AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14996265
Drug: Inhalation anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anaesthesia with sevoflurane by LMA (group S)
Trial: 10890330
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract EGb 761 (180 mg/d)
Trial: 8383769
Drug: Guava fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guava fruit intake (0.5-1.0 kg daily)
Trial: 3526853
Drug: 1.55 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.55 mg/kg cibenzoline
Trial: 3526853
Drug: 1.80 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.80 mg/kg cibenzoline
Trial: 3526853
Drug: 2.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.2 mg/kg cibenzoline
Trial: 3526853
Drug: 2.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.6 mg/kg cibenzoline
Trial: 21496312
Drug: Observation following
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation following local treatment of intracranial melanoma metastases with surgery and/or SRS
Trial: 15326260
Drug: safinamide (SAF)
DrugBank: Safinamide (DB06654)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: safinamide (SAF) 70 mg/day (range 40 to 90 mg/day)
Trial: 11531679
Drug: Metaraminol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaraminol 0.5 mg
Trial: 8315260
Drug: Alpha-interferon (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-interferon (10 MU/m2, three times weekly for 4 months)
Trial: 26342427
Drug: Ferroquine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferroquine 2 mg/kg plus artesunate
Trial: 26342427
Drug: Ferroquine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferroquine 4 mg/kg plus artesunate
Trial: 26342427
Drug: Ferroquine 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferroquine 6 mg/kg plus artesunate
Trial: 26342427
Drug: Ferroquine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferroquine 4 mg/kg monotherapy
Trial: 21454017
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive users (third generation)
Trial: 21454017
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive users (new generation)
Trial: 16414297
Drug: Inhaled glucocorticoid/beta(2)-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoid/beta(2)-adrenergic agonist combination drug
Trial: 16414297
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment) for ex-smokers with COPD
Trial: 15109558
Drug: Traditional tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional tea preparations of Artemisia annua
Trial: 11455223
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg dexamethasone premedication
Trial: 11455223
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg dexamethasone premedication
Trial: 11455223
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dexamethasone premedication
Trial: 9734750
Drug: Omeprazole treatment
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole treatment combined with phylloquinone-restricted diet
Trial: 9734750
Drug: Phylloquinone-restricted diet
RxNorm normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phylloquinone-restricted diet with omeprazole treatment
Trial: 4555981
Drug: 9-tetrahydrocannabinol administered
RxNorm normalized name: Δ9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9-tetrahydrocannabinol administered by smoking
Trial: 22379876
Drug: Standard intensive
RxNorm normalized name: MACADAMIA OIL 2 g in 100 g / CERAMIDE NP 0.0006 g in 100 g / PANTHENOL 0.75 g in 100 g / CENTELLA ASIATICA WHOLE 0.003 g in 100 g TOPICAL CREAM [ATO STANDARD INTENSIVECREAM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intensive therapy of diabetic ketoacidosis
Trial: 22379876
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy for neuroprotection by actovegin
Trial: 22379876
Drug: Reamberin on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reamberin on the background of standard therapy
Trial: 22379876
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of actovegin and reamberin
Trial: 16814082
Drug: High-dose coenzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose coenzyme Q(10) (10.0 mg/kg/day)
Trial: 16814082
Drug: Low-dose coenzyme
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose coenzyme Q(10) (1.0 mg/kg/day)
Trial: 12766622
Drug: Mecamylamine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine 7.5 mg
Trial: 12766622
Drug: Mecamylamine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine 15 mg
Trial: 9327714
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment (HBO) combined with recombinant tissue plasminogen activator (rTPA)
Trial: 30940692
Drug: GSK2292767A single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2292767A single dose (0.05-2 mg)
Trial: 30940692
Drug: GSK2292767A repeat
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2292767A repeat dose (2 mg for 14 days)
Trial: 27074126
Drug: Inositol at
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol at 80 mg/kg/d
Trial: 27074126
Drug: Inositol at
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol at 40 mg/kg/d
Trial: 27074126
Drug: Inositol at
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol at 10 mg/kg/d
Trial: 16896884
Drug: Bicalutamide 150
RxNorm normalized name: bicalutamide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150 mg adjuvant to radiotherapy
Trial: 7857734
Drug: Alacepril (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alacepril (37.5 mg)
Trial: 25232828
Drug: FOLFOX chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX chemotherapy
Trial: 24744152
Drug: Short-interval lower-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-interval lower-dose (SILD) intravenous cyclophosphamide (CYC) - 12 fortnightly pulses at 400 mg followed by 6 monthly pulses
Trial: 24744152
Drug: High-dose (HD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (HD) intravenous cyclophosphamide (CYC) - 6 monthly pulses followed by two quarterly pulses at 0.5-1.0 g/m(2)
Trial: 22113951
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg every 6 months) - long-term group
Trial: 22113951
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg every 6 months) - cross-over group
Trial: 22113951
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg every 6 months) - both groups
Trial: 15941900
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement (42 g protein, 24 g carbohydrate, 2 g fat)
Trial: 15941900
Drug: Carbohydrate supplement
RxNorm normalized name: carbohydrate supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplement (70 g carbohydrate)
Trial: 15941900
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement
Trial: 10739728
Drug: Intense insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense insulin treatment
Trial: 10739728
Drug: Standard antidiabetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antidiabetic therapy
Trial: 6131148
Drug: Lorazepam (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (4 mg intravenously)
Trial: 6131148
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg intravenously)
Trial: 25224019
Drug: Dehydrated human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dehydrated human amnion/chorion membrane allograft and multilayer compression therapy
Trial: 25224019
Drug: Multilayer compression
RxNorm normalized name: zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multilayer compression therapy alone
Trial: 22763903
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block (20 mL 0.5% ropivacaine)
Trial: 17911647
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (AmB) treatment
Trial: 17911647
Drug: Sodium antimony
RxNorm normalized name: Sodium antimonyl gluconate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium antimony gluconate (SAG) treatment
Trial: 12364969
Drug: Anal submucosal
RxNorm normalized name: Mephitis mephitis anal gland fluid preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anal submucosal injection (ASI) of amikacin 400 mg daily for ten times
Trial: 12364969
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection (IM) of amikacin 400 mg daily for ten times
Trial: 7584917
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg isosorbide‐5‐mononitrate
Trial: 7584917
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg isosorbide‐5‐mononitrate
Trial: 7584917
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide‐5‐mononitrate
Trial: 498765
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tetraethylthiuramdisulfide (Antabuse) two to four times daily for 4-10 weeks
Trial: 25862439
Drug: Treatment discontinuation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment discontinuation
Trial: 498765
Drug: Side effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side effects of Antabuse treatment
Trial: 498765
Drug: Nickel levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nickel levels during treatment
Trial: 30845329
Drug: Vi‐TCV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi‐TCV vaccine
Trial: 23460234
Drug: Milk fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fortified with 600 IU (15 μg) of vitamin D per day for 12 weeks
Trial: 23460234
Drug: Milk fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fortified with 1,000 IU (25 μg) of vitamin D per day for 12 weeks
Trial: 23460234
Drug: Unfortified milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfortified milk (control group) 200 ml per day for 12 weeks
Trial: 21280197
Drug: MTX 1
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 1 g/m² in 24 hr with intrathecal injection
Trial: 21280197
Drug: MTX 3
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 3 g/m² in 3 hr without intrathecal
Trial: 7836943
Drug: Heparin‐induced extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin‐induced extracorporeal low‐density lipoprotein/fibrinogen precipitation (HELP)
Trial: 31542640
Drug: Chemotherapy regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimens (specific regimens not detailed)
Trial: 23185280
Drug: Intravenous amantadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amantadine (400 mg/day)
Trial: 23185280
Drug: Amantadine tablet
RxNorm normalized name: amantadine Oral Tablet
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine tablet (open-label follow-up)
Trial: 21302486
Drug: Fengshikang (FSK)
RxNorm normalized name: FSK-5 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fengshikang (FSK) combined with glucocorticoid therapy
Trial: 21302486
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) with glucocorticoid therapy
Trial: 17351951
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with epirubicin, paclitaxel, and cyclophosphamide plus darbepoetin alpha
Trial: 15466946
Drug: Oats (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oats (60 g oatmeal)
Trial: 15466946
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 IU) plus Vitamin C (500 mg)
Trial: 15466946
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oats and vitamins
Trial: 10837840
Drug: Caffeinated beverages
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeinated beverages (tea and coffee with 37.5 mg and 75 mg caffeine in tea, 75 mg and 150 mg caffeine in coffee)
Trial: 10837840
Drug: Caffeinated beverages
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeinated beverages (with varying caffeine levels: 0, 25, 50, 100, and 200 mg)
Trial: 8403296
Drug: Recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant tissue plasminogen activator (rt-PA) infusion
Trial: 8403296
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with appropriate supplemental measures
Trial: 3131404
Drug: gallopamil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallopamil (10 mg)
Trial: 3131404
Drug: cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cromolyn sodium (20 mg)
Trial: 26464454
Drug: THC (Δ9-tetrahydrocannabinol)
RxNorm normalized name: Δ9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THC (Δ9-tetrahydrocannabinol) administered intravenously
Trial: 23390362
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (6-month, twice weekly)
Trial: 9640082
Drug: NAG urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAG urine activity in patients with massive proteinuria (> 1.5 g/24 h)
Trial: 9640082
Drug: NAG values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAG values above and below 280 nmol/mg of creatinine
Trial: 9640082
Drug: NAG values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAG values higher than 280 nmol/mg of creatinine
Trial: 29542334
Drug: Non-biologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-biologic treatment plans (glucocorticoids alone and methotrexate)
Trial: 29542334
Drug: Biologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic treatment plans (interleukin-1 blockade and interleukin-6 blockade)
Trial: 28599712
Drug: 0.65-g alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.65-g alcohol dose/kg body weight
Trial: 26534969
Drug: Modafinil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (400 mg for 90 days)
Trial: 9366542
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (PEG) preparations
Trial: 1583824
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of ST-segment elevation by 50% after 2 hours of treatment
Trial: 30570839
Drug: Brigatinib 180
RxNorm normalized name: brigatinib 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 180 mg after a high-fat meal
Trial: 30570839
Drug: Brigatinib 180
RxNorm normalized name: brigatinib 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 180 mg after fasting
Trial: 30570839
Drug: Treatment-emergent adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent adverse events under fasted conditions
Trial: 30570839
Drug: Treatment-emergent adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent adverse events under fed conditions
Trial: 30518514
Drug: SlowMo therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SlowMo therapy (new intervention)
Trial: 24550332
Drug: Cobicistat (COBI)‐boosted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobicistat (COBI)‐boosted Elvitegravir (EVG/co) (150/150 mg) administered once daily for 10 days
Trial: 19953610
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block (BSCPB) with 20 mL of 0.75% ropivacaine
Trial: 17179200
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone therapy (50 microg daily)
Trial: 14693980
Drug: SU plus
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU plus metformin
Trial: 9678311
Drug: Apolipoprotein E
RxNorm normalized name: Apolipoprotein E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apolipoprotein E epsilon4 allele dose
Trial: 8036454
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg at 1830 h)
Trial: 22381489
Drug: Low-intensity laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity laser therapy (infrared radiation from a semiconductor diode laser with a wavelength of 810 nm), applied on days 0, 3, 7, and 14 in the first month, and thereafter on every 15th day until complete canine retraction was achieved.
Trial: 22381489
Drug: Control side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control side (no low-intensity laser therapy applied).
Trial: 9534293
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg + Hydrochlorothiazide 25 mg (L-HCTZ Group)
Trial: 9588918
Drug: High-dose proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose proton and photon irradiation (66.6 or 72 cobalt Gray equivalent, 1.8 CGE/day, 5 fractions/week)
Trial: 9588918
Drug: High-dose proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose proton and photon irradiation
Trial: 1927914
Drug: Ionic low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic low osmolar contrast agent ioxaglate (n = 50)
Trial: 30676838
Drug: High-dose investigational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose investigational Sabin IPV (group A)
Trial: 30676838
Drug: Medium-dose investigational
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose investigational Sabin IPV (group B)
Trial: 30676838
Drug: Low-dose investigational
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose investigational Sabin IPV (group C)
Trial: 20878446
Drug: Protracted dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protracted dose-dense temozolomide therapy (100 mg/m² for 21 consecutive days of a 28-day cycle)
Trial: 20878446
Drug: Protracted dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protracted dose-dense temozolomide therapy
Trial: 19170737
Drug: Clobazam (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (high dose = target 1.0 mg/kg/day)
Trial: 19170737
Drug: Clobazam (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (low dose = target 0.25 mg/kg/day)
Trial: 19170737
Drug: Clobazam (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (high dose)
Trial: 19170737
Drug: Clobazam (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (low dose)
Trial: 19170737
Drug: Clobazam (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (both doses)
Trial: 14767877
Drug: 1.5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/d n3PUFA